Fit-for-purpose expertise

David Miller, PhD is our Chairman and Chief Executive Officer. Prior to Genesis Research Group, David was Senior Vice President of Global Market Access at Biogen. He previously founded a consultancy delivering business and commercial strategies for biopharmaceutical clients and served as Vice President of Pharmacoeconomics; Managing Director, Asset Executive; and Head of International Operations at Elan. David began his career at GSK, culminating in his role as Vice President of Global Health Outcomes.

Frank A. Corvino is our Co-Founder and Vice Chairman. A quantitative scientist by training, he has spent the last 15 years advancing the way epidemiology, health outcomes, medical affairs and market access leverage RWE for decision-making and stakeholder communications. He has published frequently in Mathematics, Physics, Statistics and Healthcare, and held academic positions at the City University of New York and Stevens Institute of Technology, where he also received his PhD. He holds an MBA from Columbia Business School.

Jennifer Fillman MBA is a highly respected executive with over 27 years of corporate, financial, and business experience, including as a general manager for pharmaceutical business units and as Senior Vice President and CFO of a contract research organization’s largest operating segment. She has significant experience in scaling pharmaceutical services businesses to maximize growth potential.

Deb Casso provides scientific and operational direction for RWE strategy, generation, synthesis, and scientific communications. She has more than 30 years of experience in the design and conduct of observational research studies, including 15 years of experience partnering with life sciences clients on the design, conduct, and strategic considerations of pharmaco-epidemiology and drug safety studies and the use of RWE for both pre- and post-approval regulatory decision-making. Deb has an MPH in Epidemiology from the University of Washington.

Tim Wright leads our Access & Pricing division. An economist and health economist, Tim has worked in the bioscience sector for over 30 years including industry roles in clinical research, EU pricing, and reimbursement, as Head of UK HEOR, Global P&MA Director for two mega-brands, and as Global P&MA Director, early portfolio. Tim also has 18 years in senior executive roles within strategic P&MA consultancies. During his tenure Tim has led over 1,000 engagements across all major therapy areas, as well as rare, orphan, and ultra-orphan diseases.

For the past decade, Michael has been fostering company growth on a number of ongoing client relationships, supporting the organization from both the UK and US. He works on talent acquisition, company culture, and employee life. He also introduces executable strategies that harmonize business practices to best deliver client solutions.